

October 15, 2018

| | |
|---|---|
| The National Stock Exchange of India Exchange Plaza, Plot No. C/1, G Block Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 | BSE Limited Listing Department P.J. Towers, 1 st Floor, Dalal Street, Fort, Mumbai – 400 001 |
|---|---|

Scrip Symbol: THYROCARE

Security Code:

539871

Dear Sir/Madam

Sub: Intimation of completion of buyback by Thyrocare Technologies Limited (“Company”) of its equity shares from the open market through the stock exchange mechanism in accordance with the Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 (“Buyback Regulations”), as amended.

This is in furtherance to (i) our letter dated August 4, 2018 disclosing the outcome of the board meeting held on the same day and our letter dated September 1, 2018 disclosing the outcome of the shareholders meeting that approved *inter alia* the Buyback; and (ii) Public Announcement published on September 11, 2018 in relation to the Buyback.

Pursuant to the provisions of Sections 68, 69, 70, and all other applicable provisions, if any, of the Companies Act, 2013, as amended (“**Companies Act**”) and applicable rules thereunder, and the provisions of the Buyback Regulations, Article 13 of the articles of association of the Company, and pursuant to the resolutions passed by the board of directors of Thyrocare Technologies Limited (the “**Company**”) (the Board of Directors of the Company are hereinafter referred to as the “**Board**” or the “**Board of Directors**”) at their meeting held on August 4, 2018 (the “**Board Meeting**”), the Board sought approval of the shareholders of the Company at its annual general meeting held on September 1, 2018 (“**General Meeting**”) for the proposal of the buyback of Equity Shares. The shareholders had, in the General Meeting held on September 01, 2018, approved the said proposal of the buyback of the Company’s fully paid-up equity shares of face value of Rs.10 each (Rupees Ten only) (the “**Equity Shares**”) from its shareholders/beneficial owners, other than those who are promoters or the persons in control of the Company and promoter group (hereinafter collectively referred to as the “**Promoters**”), from the open market through stock exchange mechanism i.e. using the electronic trading facilities of the Stock Exchanges for a total amount not exceeding Rs. 63,00,00,000/- (Rupees Sixty Three Crore only) (the “**Maximum Buyback Size**”), and at a price not exceeding Rs.730/- (Rupees Seven Hundred and Thirty only) per Equity Share (“**Maximum Buyback Price**”), payable in cash (the process being referred hereinafter as “**Buyback**”). The Maximum Buyback Size and Maximum Buyback Price do not include brokerage costs, applicable taxes such as securities transaction tax, goods and service tax, stamp duty and other transaction charges (collectively referred to as “**Transaction Costs**”).



Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)

The Buyback commenced on September 24, 2018 in accordance with the procedure provided in the Buyback Regulations. In this regard, please be informed that till date, the Company has bought back 9,58,900 Equity Shares and deployed an amount of Rs. 62,99,99,729 (Rupees Sixty Two crores Ninety Nine Lakhs Ninety Nine Thousand Seven Hundred and Twenty Nine only), which represents approximately 99.99% of the Maximum Buyback Size. Consequently, the Company announces the closure of the Buyback today, i.e., October 15, 2018.

For details of the pre and post Buyback shareholding pattern of the Company, please see Annexure.

We request you to kindly take this on record.

Yours Sincerely

Thanking You,

For Thyrocare Technologies Limited



Ramjee Dorai

Company Secretary & Compliance Officer.



ANNEXURE

The shareholding pattern of the Company both pre and post the Buyback:

| Shareholder | Pre-Buyback | | Post completion of the Buyback | |
|---|----------------------|--------------------|--------------------------------|--------------------|
| | No. of Equity Shares | % of Equity Shares | No. of Equity Shares | % of Equity Shares |
| (A) Promoter & Promoter Group | 34,361,745 | 63.96% | 34,361,745 | 65.12 |
| (B) Public | 19,360,780 | 36.04% | 18,401,880 | 34.88 |
| (C1) Shares underlying DRs | 0 | 0.00 | 0 | 0.00 |
| (C2) Shares held by Employee Trust | 0 | 0.00 | 0 | 0.00 |
| (C3) Trading Members and Associate of Trading Members | 0 | 0.00 | 0 | 0.00 |
| (C) Non-Promoter -Non-Public (C = C1+C2+C3) | 1,008 | 0.00 | 1,008 | 0.00 |
| Grand Total (A+B+C) | 53,723,533 | 100.00 | 52,764,633 | 100.00 |

For Thyrocare Technologies Limited



Ramjee Dorai

Company Secretary & Compliance Officer.



Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)